Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma
OBJECTIVES: I. Determine the response rate and response duration of patients with refractory
or relapsed multiple myeloma treated with SU5416. II. Determine the toxicity of SU5416 in
this patient population.
OUTLINE: This is a multicenter study. Patients receive SU5416 IV over 1 hour twice weekly.
Treatment continues in the absence of unacceptable toxicity or disease progression. Patients
are followed for survival.
PROJECTED ACCRUAL: A total of 20-38 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Mitchell R. Smith, MD, PhD
Fox Chase Cancer Center
United States: Federal Government
|H. Lee Moffitt Cancer Center and Research Institute||Tampa, Florida 33612|
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|